Factor X (FX) is a vitamin K-dependent plasma protein required for the intrinsic and extrinsic pathways of blood coagulation. FXSanto Domingo is a hereditary FX deficiency which is characterized clinically by a severe bleeding diathesis. The proposita has a FX activity of less than 1% and a FX antigen of less than 5%. We have determined the molecular basis of the defect in the FXSanto Domingo gene by amplification of all eight exons with polymerase chain reaction and subsequent sequence analysis. The patient is homozygous for a G----A transition in exon I at codon -20 (numbering the alanine at the NH2 terminus of the mature protein as +1), resulting in the substitution of arginine for glycine in the carboxy-terminal part of the signal peptide. This amino acid change occurs near the presumed cleavage site of the signal peptidase. We hypothesized that the mutation might prevent cleavage by the signal peptidase which in turn would impair proper secretion of the FX protein. To test this hypothesis, we compared the expression of wild type and mutant FX cDNA in a human kidney cell line. Wild type and mutant constructs in the expression vector pCMV4 were introduced into the human embryonic kidney cell line 293 by calcium phosphate transfection. FX antigen levels in the supernatant of the cells harboring the wild type construct […] 
Introduction
Factor X (FX) is a vitamin K-dependent plasma protein required for the intrinsic and extrinsic pathways of blood coagulation. F~s.. Di,.w is a hereditary FX deficiency which is characterized clinically by a severe bleeding diathesis. The proposita has a FX activity of < 1% and a FX antigen of < 5%. We have determined the molecular basis of the defect in the FXst. D.h,,gene by amplification of all eight exons with polymerase chain reaction and subsequent sequence analysis. The patient is homozygous for a G -* A transition in exon I at codon -20 (numbering the alanine at the NH2 terminus of the mature protein as +1), resulting in the substitution of arginine for glycine in the carboxy-terminal part of the signal peptide. This amino acid change occurs near the presumed cleavage site of the signal peptidase. We hypothesized that the mutation might prevent cleavage by the signal peptidase which in turn would impair proper secretion of the FX protein. To test this hypothesis, we compared the expression of wild type and mutant FX cDNA in a human kidney cell line. Wild type and mutant constructs in the expression vector pCMV4 were introduced into the human embryonic kidney cell line 293 by calcium phosphate transfection. FX antigen levels in the supernatant of the cells harboring the wild type construct were 2.4 ig/10' cells per 24 h, whereas antigen levels in media from cells containing the FXAsDT construct were undetectable. No FX antigen was detected in the cell lysates of cells transfected with the mutant construct. To insure that the difference in protein levels was not due to a difference in steady state levels of mRNA, Northern analysis was performed on RNA from the cell lysates of both constructs. The results showed a transcript of the same size, present in roughly equal amounts, in both cases. Thus, the defect in the signal sequence of Daub D exerts its effect posttranscriptionally. F7so Do_ is the first described example of a bleeding diathesis due to a mutation in the signal sequence. (J. Clin. Invest. 1991. 88:1685-1689.) Key words: factor X * signal sequence * bleeding diathesis * factor X deficiency Factor X (FX)' is a vitamin K-dependent plasma glycoprotein required for blood coagulation (1) . It is synthesized in hepatocytes as a single polypeptide chain, or prepro-FX, and undergoes several modifications before it is constitutively secreted into plasma. In a cotranslational event, the signal sequence is cleaved off from the NH2-terminal portion of the primary translational product ofFX. Further posttranslational steps include y-carboxylation of 11 glutamic acid residues located near the NH2 terminus, cleavage of the propeptide, glycosylation, and beta hydroxylation. The amino acid sequence of FX has been derived from FX cDNA's and direct amino acid analysis (2) (3) (4) (5) . The gene has also been isolated and partially characterized. It has been mapped to chromosome 1 3q32-qter (6) , where it spans 25 kb; it consists of seven introns and eight exons and has structural homology with the genes encoding the other vitamin K-dependent clotting factors (7) . The functional domains of the protein are represented by different exons: exon I codes for the signal sequence, exon H for the propeptide, and the y-carboxyglutamic acid-rich domain, exon III for the short aromatic acid-rich stack, exons IV and V for the epidermal growth factor-like domains, exon VI for the activation peptide, and exons VII and VIII for the catalytic domain (7) .
Congenital FX deficiency is inherited as an autosomal recessive trait (8) . Considerable phenotypic heterogeneity exists among FX variants (9-1 1). The molecular basis of congenital FX deficiency has been completely elucidated in only three families so far. Two of these are homozygous for defects in exon 11 (12) and exon VIII (13) , respectively. One compound heterozygote has been reported (14) . Here we report another homozygous FX deficiency (FXs.,. Donna b) in which a point mutation in exon I leads to a severe bleeding disorder in the affected proposita.
Methods
Patient data. The proposita is a 16-yr-old female from Santo Domingo, Dominican Republic, who came to medical attention because ofheavy menstrual bleeding at menarche. This was associated with significant blood loss, requiring transfusion, and on occasion, treatment with prothrombin complex concentrates. Blood samples were obtained from the proposita and her parents after informed consent. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed using standard methods. FX antigen levels were determined by immunoassay using a FX-specific sandwich ELISA. Four different monoclonal antibodies were used as capture antibodies (gift of Dr. William Church, University of Vermont, and Dr. D. M. Monroe, University ofNorth Carolina). One ofthese has been extensively characterized and recognizes an epitope in the heavy chain (15) ; the other three also recognize epitopes in the heavy chain. Plates are coated first with 1. Abbreviations used in this paper: aPTT, activated partial thromboplastin time; FX, Factor X; PT, prothrombin; TBE, Tris-borate-EDTA buffer.
the monoclonal antibody; the second antibody is a rabbit polyclonal anti-human FX (12) . Factor X activity levels were determined using a one-stage clotting assay. DNA analysis. Genomic DNA was prepared from the patients' peripheral blood using standard methods (16) , and Southern blots were performed to determine whether the gene was grossly intact. 10 jig of genomic DNA from the proposita and the same amount from a nonrelated normal control were digested with 30 U ofEco RI at 370C for 3 h.
The digest was electrophoresed on a 0.8% agarose gel and transferred to a nitrocellulose membrane according to the method of Southern (17) . A full-length human FX cDNA (gift of Dr. D. Stafford) was radiolabelled with 32P dCTP by random priming using the manufacturer's conditions (Boehringer-Mannheim Biochemicals, Indianapolis, IN). 20 ng of labelled probe with a sp act of 1.8 X 109 cpm/jig was added to the filter incubating in 6X SSC, 0.01 M EDTA, 0.1 M K2H2P04, SX Denhardt's solution, 0.5% SDS, and 250 jug/mi salmon sperm DNA. After incubation for 12 h at 680C the filter was washed in 2x SSC, 0.5% SDS twice for 15 min at room temperature, in 0. X SSC, 0.5% SDS for 45 min at 680C, and exposed to x-ray film at -70'C for 24 h.
All eight exons of FX were isolated using the enzymatic amplification technique (18) . Synthetic oligonucleotides derived from intron sequences flanking the 5' and 3' ends of each exon were used to prime amplification (12) . Hind III restriction sites were built in at the 5' ends of each oligonucleotide. Target sequences were amplified in a 100-jil volume containing 1 jig ofgenomic DNA, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 2.5 mM MgC12, 0.01% (wt/vol) gelatin, 0.2 jiM of each deoxyribonucleotide (dNTP:dCTP, dGTP, dATP, dTTP), 1 jiM of each primer, and 1 U Taq polymerase. The samples were overlaid with 100 jIl mineral oil to prevent evaporation and subjected to 30 cycles of denaturation at 94°C for 2 min, annealing at 55°C for 2 min, and primer extension at 72°C for 3 min on a DNA Thermal Cycler R (Perkin-Elmer Cetus, Emeryville, CA). The amplified DNA was electrophoresed on a 2% agarose gel in Tris-borate-EDTA buffer (TBE) and the amplified region cut out from the gel. The recovered gel slice was crushed and incubated with 50 jl TBE, 50 jl phenol, and 50 ji chloroform:isoamyl alcohol (24:1) for 15 min at -70°C. After spinning for 15 min in a microfuge the supernatant was recovered and the DNA precipitated with ethanol. After digestion with Hind III the fragments were subcloned into M13 sequencing vectors and sequenced as previously described (19) .
Exon I was also amplified as described above to perform restriction analysis with Dde I. 30 base synthetic oligonucleotides derived from the 5' untranslated region and from intron A were used in this amplification to yield a DNA fragment of 213 bp containing exon I and a single naturally occurring Dde I site. DNA fragments were electrophoresed and purified as described above. Digestions were carried out according to the manufacturer's conditions with Dde I (New England Biolabs, Beverly, MA). Digested DNA was electrophoresed on a 6% agarose gel (Nu Sieve GTG; FMC Corp., FMC BioProducts, Rockland, ME) in TBE buffer. Exon I amplified from normal DNA was used as a control in all restriction digests.
In vitro expression. A partial human FX cDNA which contains the complete FX coding sequence, a translation initiation sequence, and part of the 3' untranslated region was inserted in the multiple cloning site of the phagemid pMA254. The point mutation found in exon I of the FXst. Dowl gene was introduced into the pMA254-FX plasmid by oligonucleotide hybridization (20) and the gapped duplex method. The presence of the point mutation in the mutagenized plasmid was confirmed by DNA sequence analysis. The plasmid pCMV4 was used as the expression vector (21 The constructs were introduced into the human embryonic kidney cell line 293 by calcium phosphate transfection (22) . All transfections were done in duplicate. A mock transfection (no DNA) served as a control. Cells were grown in DMEM/F12 medium in the presence of 10% FCS. 24 h before collecting samples, culture medium was changed and fetal calf serum was omitted to eliminate any possibility of antibody cross-reactivity with bovine FX. The supernatant was collected 72 h after transfection and analyzed for the presence of FX antigen, using the immunoassay described above. The transfected cells were also collected, lysed, and assayed for the presence of FX. For the cell lysis procedure, confluent cells in a 10-cm dish were washed twice with PBS, then covered with buffer containing 0.5% NP-40, 60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCI, 1 mM MgSO4, and 50 mM 2-mercaptoethanol. The cells were scraped from the plate and centrifuged at 12,000 g for 15 min at 40C. FX antigen levels in the supernatant were determined. Total RNA was isolated from the transfected cells by the guanidinum-phenol-chloroform method (23). 10 jig oftotal RNA was loaded on a formaldehyde-agarose (1%) gel and electrophoresed for 2 h at 75 V. RNA was transferred onto a nitrocellulose filter, probed with a radiolabelled FX cDNA, and exposed to x-ray film at -70'C for 12 h.
Results
Clinical data and gene analysis. Results of coagulation studies are described in Table I . The proposita has a markedly prolonged PT and aPTT. Factor assays revealed a FX activity of < 1%; the activities ofall other coagulation factors were within normal limits. The parents both had FX activity levels in an intermediate range, 29 -38%. The FX antigen levels were 5% of normal in the proposita and 50% of normal in the parents (Table I) . Southern blot analysis of the proposita's EcoRI digested DNA probed with an FX cDNA showed the same pattern of bands as normal DNA (data not shown). Thus, there is no evidence of a gross gene deletion, insertion or rearrangement.
Sequence analysis ofthe coding region and the exon-intron junctions ofthe proposita's FX gene revealed a single base mismatch when compared with the normal sequence. A G --A point mutation at the first nucleotide of codon -20 results in the substitution ofan arginine (AGG) for a glycine (GGG) (Fig.  1) . The mutation creates a new Dde I restriction site within exon I (Fig. 1) . Enzymatically amplified exon I from a mutant allele therefore shows one additional Dde I site which can be used for discrimination between a normal, a homozygous, and a heterozygous genotype with respect to the mutation in exon I. Dde I restriction of DNA amplified from exon I of a normal control showed DNA fragments of 113 bp and 100 bp due to the naturally occurring Dde I site (Fig. 2) . In the DNA amplified from exon I of the proposita, the 100-bp fragment was further cleaved into fragments of 70 bp and 30 bp due to the (Table II) . The wild type FX construct yielded a FX antigen concentration in the cell supernatant of 300 ng/ml per 24 h. Normalized to the number ofcells, this concentration represents 2.4 ,ug FX antigen/107 cells per 24 h. In contrast, no FX antigen was detectable in the supernatant of the cells that were transfected with the FXsnto Domino construct. The lower limit of detection of the ELISA is 10 ng/ml. When the transfected cells were lysed and assayed for the presence of FX, no FX protein was detectable in the cells transfected with the Santo Domingo construct. FX was present in the cells transfected with the wild type construct at a concentration of 300 ng/ml. Northern blot analysis ofcell lysates showed a FX mRNA of the same size, present in roughly equal amounts, in both the wild type and the Santo Domingo transfectants (Fig. 3) has been completely elucidated at the molecular level (12) (13) (14) .
It is the first mutation in a FX deficiency, however, in which the causative effect ofthe mutation has been proved by expression in vitro of the mutant cDNA and subsequent analysis of the expressed phenotype. The results of our expression experiments in vitro parallel the situation in vivo, as the lack of FX expression in vitro correlates well with the low FX antigen levels in the plasma of the proposita. We therefore conclude that the point mutation in exon I and the resulting substitution of arginine for glycine at position -20 (numbering the alanine at the NH2 terminus of the mature protein as +1) cause the FXsantO Domingo phenotype.
Amino acid -20 is part of the prepro region of the FX protein. The signal sequence serves the function of targeting the elongating polypeptide chain to the site of translocation into the endoplasmic reticulum, where a number of critical posttranslational steps occur. The signal sequence is cleaved from the protein in a cotranslational event (24) as the newly synthesized protein is translocated into the lumen ofthe endoplasmic reticulum. The propeptide, which is still attached and serves as a recognition site for the 'y-carboxylase (25) , is cleaved _____ in a subsequent posttranslational modification. While the NH2 terminus ofthe mature protein unambiguously indicates where 'PIropo-the propeptide is cleaved, the cleavage site of the signal se- quence in the human prepro FX has not been established with certainty. Several lines of evidence suggest that the signal peptidase cleavage site is located between Ser(-18) and Leu(-17). First, organization of the FX gene follows a structure-function pattern whereby the coding regions for the various functional domains ofthe FX protein are found in different exons (7) . Exon I encodes the signal peptide domain ofall vitamin K-dependent coagulation factors. Exon I in the FX gene codes for amino acids Met(-40) through Leu(-18). Thus, exon I exactly encodes the complete signal sequence assuming the signal peptidase cleavage site is COOH-terminal to Leu(-18). Second, the COOH termini of signal sequences are characterized by small, neutral amino acid residues at positions -1 and -3 (numbering the very COOH-terminal amino acid of the signal sequence as -1) (26). The conservation of small neutral amino acids at these residues is sometimes referred to as the -1, -3 rule. In aligning various signal sequences, von Heijne was able to empirically develop rules that allow prediction ofthe actual cleavage site ofthe signal sequence by signal peptidase (26). Application ofthese rules to FX predicts a highly favorable cleavage site for the signal peptidase between residues -18 and -17 (Fig. 4) . Finally, presumption of cleavage at this point is further supported by the fact that the bovine FX signal sequence, which is very similar to the human FX signal sequence, has been reported to be cleaved exactly at this point (27) . The substitution of Arg for Gly, occurring at residue -20 numbering from the NH2 terminus of the mature protein, falls at the critical -3 residue, numbering from the presumed COOH terminus of the signal sequence. Consistent with the -1, -3 rule, amino acid -3 is a small neutral residue in the majority ofprokaryotic and eukaryotic signal sequences. Based on data generated in prokaryotic systems, the Gly Arg mutation at -3 is predicted to impair processing profoundly. An Ala Arg mutation at -3 ofthe maltose bindingprotein in Escherichia coli results in extremely inefficient processing, with only 7% of premaltose binding protein being cleaved to mature product (28) . More conservative substitutions, e.g., glycine, valine, leucine, had no effect on processing. One (12) (13) (14) 32) . Further study ofthis mutation may yield additional insights into the mechanism of action of signal sequences.
